The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin–angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update
Journal of Biomedical Science Open Access 13 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Navarro-González, J. et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN Trial. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014010012.
Gregg, E. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).
Vejakama, P. et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55, 566–578 (2012).
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C. & Egido, J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat. Rev. Neph. 10, 325–346 (2014).
Abdel-Salam, O. M., Baiuomy, A. R., El-Shenawy, S. M. & Arbid, M. S. The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol. Res. 47, 331–340 (2003).
Shan, D. et al. Pentoxifylline for diabetic kidney disease. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD006800. http://dx.doi.org/10.1002/14651858.CD006800.pub2.
Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540–1546 (2007).
Perkovic, V. et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517–523 (2013).
Cowie, C. C. et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N. Engl. J. Med. 321, 1074–1079 (1989).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
He, T., Cooper, M. Renoprotective effects of pentoxifylline in the PREDIAN trial. Nat Rev Nephrol 10, 547–548 (2014). https://doi.org/10.1038/nrneph.2014.162
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.162
This article is cited by
-
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update
Journal of Biomedical Science (2017)